Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating expenses:        
Research and development $ 984,278 $ 1,316,520 $ 3,081,366 $ 4,564,602
General and administrative 590,624 749,474 2,005,711 2,354,645
Total operating expenses 1,574,902 2,065,994 5,087,077 6,919,247
Loss from operations (1,574,902) (2,065,994) (5,087,077) (6,919,247)
Other income 171,282 0 171,282 0
Interest income 99,344 112,260 254,984 330,966
Net loss (1,304,276) (1,953,734) (4,660,811) (6,588,281)
Other comprehensive income (loss):        
Foreign currency translation gain (loss) 5,176 6,930 5,924 (8,254)
Unrealized gain (loss) on investments (24,425) (10,203) (2,783) 3,261
Comprehensive loss $ (1,323,525) $ (1,957,007) $ (4,657,670) $ (6,593,274)
Net loss per share:        
Basic and diluted (in dollars per share) $ (0.37) $ (0.69) $ (1.36) $ (2.43)
Weighted average shares outstanding:        
Basic and diluted** (in shares) 3,520,398 2,823,680 3,419,321 2,710,356